
    
      Prospective, randomized, parallel group, double-dummy, placebo and active-controlled (Detrol
      LA - tolterodine) trial wherein patients with OAB or UUI will receive single daily does of
      either SSR240600C 500 mg, tolterodine 4 mg or placebo for four weeks. Baseline and end of
      study cystometry will be performed; daily symptom diaries will be completed during the trial
      and health-related quality of life will be measured before and after study drug treatment.
      Patients will be followed-up one week after completion of the trial. Study participation will
      include 5 visits over a period of six weeks.
    
  